TABLE 1.
Clinical characteristics of subjects taking suvorexant
| CHARACTERISTIC | ALL ENROLLED SUBJECTS | COMPLETED 4 WEEK FOLLOW-UP SUBJECTS | COMPLETED 8 WEEK FOLLOW-UP SUBJECTS |
|---|---|---|---|
| Number of subjects | 40 | 37 | 26 |
| Age years, mean ± SD | 55.2±18.3 | 53.4±17.5 | 54.6±16.9 |
| Sex, n (%) | |||
| Male | 24 (60.0) | 21 (56.8) | 11 (42.3) |
| Female | 16 (40.0) | 16 (43.2) | 15 (57.7) |
| ICD-diagnosis, n (%) | |||
| F0 | 2 (5.0) | 1 (2.7) | 0 (0.0) |
| F1 | 7 (17.5) | 6 (16.2) | 3 (11.5) |
| F2 | 12 (30.0) | 12 (32.4) | 10 (38.5) |
| F3 | 16 (40.0) | 15 (40.6) | 10 (38.5) |
| F4 | 3 (7.5) | 3 (8.1) | 3 (11.5) |
| Concomitant psychiatric drugs, n | |||
| none | 2 | 1 | 0 |
| antipsychotic | 3 | 3 | 3 |
| antidepressant | 2 | 2 | 2 |
| mood stabilizer | 2 | 2 | 2 |
| anxiolytic/hypnotic | 3 | 2 | 0 |
| antipsychotic+antidepressant | 2 | 2 | 1 |
| antipsychotic+mood stabilizer | 5 | 5 | 5 |
| antipsychotic+anxiolytic/hypnotic | 3 | 3 | 2 |
| antidepressant+mood stabilizer | 1 | 1 | 0 |
| antidepressant+anxiolytic/hypnotic | 5 | 4 | 2 |
| mood stabilizer+anxiolytic/hypnotic | 1 | 1 | 1 |
| antipsychotic+antidepressant+mood stabilizer | 1 | 1 | 1 |
| antipsychotic+antidepressant+anxiolytic/hypnotic | 2 | 2 | 1 |
| antipsychotic+mood stabilizer+anxiolytic/hypnotic | 5 | 5 | 4 |
| antidepressant+mood stabilizer+anxiolytic/hypnotic | 2 | 2 | 2 |
| All | 1 | 1 | 0 |
| Suvorexant Dose mg, n (%) | |||
| 15mg | 18 (45.0) | 15 (40.5) | 12 (46.2) |
| 20mg | 22 (55.0) | 22 (59.5) | 14 (53.8) |